glp 1 market share by company Lilly's GLP-1 portfolio gains ground on Novo Nordisk GLP-1 Receptor Agonist Market Size,

What works perfectly for one person might need tweaking for another, especially as your body continues adapting to GLP-1 treatment

Pancreatic DPP-4 As well as influencing glucose homeostasis through its more widespread systemic effects, as discussed above, there is some evidence to suggest that DPP-4 may have local actions in the endocrine pancreas

Some patients report increased loose stools after starting GLP-1s due to slower gastric emptying combined with continuous bile flow

Moreover, liraglutide slightly slowed the decline in eGFR over time compared to placebo, with a baseline to month 36 ratio of 0.89 with liraglutide and 0.88 with placebo (difference of 1.015, p = 0.013)

Tirzepatide stands out for its dual action, targeting both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors